RHD kills 240,000 people annually, mostly in Africa, and is entirely preventable...
Africa Trials
2
US Trials
29
Gap Ratio
14x
Nations
54
Key Finding
Africa hosted 2 rheumatic heart disease trials versus 29 in the United States, a 14-fold disparity in research investment.
Regional Comparison
Distribution Analysis
Inequality Profile
Temporal & Structural
Why It Matters
RHD kills 240,000 people annually, mostly in Africa, and is entirely preventable with penicillin prophylaxis — yet trial investment in delivery strategies is almost nonexistent.
The Evidence 142 words · target 156
In the burden-versus-investment landscape of African health research, does the distribution of rheumatic heart disease trials across African nations reveal a systematic research gap? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa hosted 2 rheumatic heart disease trials (0.0% of its portfolio) compared to 29 in the United States, yielding a 0.0-fold disparity in per-population investment. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa. Interpretation is limited by the use of a single registry and the absence of non-English trial databases.
Sentence Structure
Question
In the burden-versus-investment landscape of African health research, does the distribution of rheumatic heart disease trials across African nations reveal a systematic research gap?
Dataset
This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.
Method
gov through April 2026.
Primary Result
Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.
Robustness
Africa hosted 2 rheumatic heart disease trials (0.
Interpretation
0% of its portfolio) compared to 29 in the United States, yielding a 0.
Boundary
0-fold disparity in per-population investment.
Extra
Temporal analysis showed 17.
Extra
1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.
Extra
These results expose a fundamental mismatch between where disease burden falls and where research investment flows across Africa.
Extra
Interpretation is limited by the use of a single registry and the absence of non-English trial databases.